- Target disease: Cutaneous Leishmaniasis (CL)
- Main partners (since project start): Programa de Estudio y Control de Enfermedades Tropicales, Universidad de Antioquia, Medellin, Colombia and Universidad Peruana Cayetano Heredia, Lima, Peru.
- Project Start: June 2015
- Funding (since project start): Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders.
When administrated alone, the safety and efficacy profiles of current CL treatments (antimonials, miltefosine, and thermotherapy) are well established. Using a combination of therapeutic approaches may improve efficacy rates, reduce treatment duration, and improve the rate of adverse events. A combination of one single application of thermotherapy at 50°C for 30 seconds with a three-week course of oral miltefosine will be tested in order to gain information about safety and efficacy.
At the end of 2016, official approvals were obtained, a site initiation visit conducted and the first patients were enrolled in Peru, while final approvals are expected by early 2017 for a second site in Colombia.
Last update: February 2017